BG
NPCE icon

Bellevue Group’s Neuropace NPCE Stock Holding History

Bellevue Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-388,368
Closed -$1.46M – 175
2022
Q3 		$1.46M Sell
388,368
-119,562
-24% -$576K 0.02% 128
2022
Q2 		$2.51M Hold
507,930
– – 0.04% 124
2022
Q1 		$4.17M Hold
507,930
– – 0.05% 122
2021
Q4 		$5.12M Hold
507,930
– – 0.05% 127
2021
Q3 		$8.05M Hold
507,930
– – 0.08% 122
2021
Q2 		$12.1M Buy
+507,930
New +$11.8M 0.12% 122

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group's NPCE Position: Q4 2022 in Review

Bellevue Group sold out of Neuropace (NPCE) in Q4 2022, closing a stake of 388,368 shares — an estimated $1.46M sold.

Bellevue Group first reported a position in NPCE in Q2 2021 and held it in 6 quarters. The position peaked at $12.1M in Q2 2021. 24 funds tracked by Wall St. Rank hold NPCE as of Q4 2022.

  • Bellevue Group reported no remaining Neuropace position as of Q4 2022 after selling out during the quarter.
  • Bellevue Group sold 388,368 Neuropace shares in Q4 2022, an estimated $1.46M.
  • Bellevue Group first reported a position in Neuropace in Q2 2021 and held it in 6 quarters.
  • Bellevue Group's Neuropace position peaked at $12.1M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Neuropace as of Q4 2022.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.